A 34-year-old female patient presents for treatment. She has been on and off medication for schizophrenia for years but has historically been non-adherent to pharmacotherapy because of the adverse effects. When considering olanzapine therapy for this patient, the PMHNP advises that she will need to be monitored for: 

A. Absolute neutrophil count (ANC)

B. Hypertension, hyponatremia and hypertriglyceridemia 

C. Extrapyramidal symptoms and irregular menses 

D. Weight gain, hyperglycemia and dyslipidemia 

---

YouTube: https://www.youtube.com/watch?v=IfnGkx6WfrY&list=PLf0PFEPBXfq5HGfNV-GbOlYHtDwd35OeG&index=58